Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.43 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 5/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.37 |
| ▸ | WNT1 | P04628 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 2/20 | 0.37 |
| ▸ | CLK3 | P49761 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15145595 | 0.98 | ALOX15 (0.49) | ALOX15GAASMN1; SMN2KDM5ABMPR1A | |
| SCHEMBL30962782 | 0.94 | ALOX15 (0.45) | ALOX15GAASMN1; SMN2KDM5ABMPR1A | |
| SCHEMBL15244353 | 0.94 | ALOX15 (0.45) | ALOX15GAASMN1; SMN2KDM5ABMPR1A | |
| SCHEMBL31361718 | 0.90 | KDM5A (0.47) | ALOX15GAASMN1; SMN2KDM5ABMPR1A | |
| SCHEMBL9953033 | 0.90 | KDM5A (0.47) | ALOX15GAASMN1; SMN2KDM5ABMPR1A | |
| SCHEMBL23685815 | 0.90 | KDM5A (0.47) | ALOX15GAASMN1; SMN2KDM5ABMPR1A | |
| SCHEMBL1703008 | 0.85 | ALOX15 (0.39) | ALOX15GAASMN1; SMN2KDM5ABMPR1A | |
| SCHEMBL173506 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL25243994 | 0.83 | PIK3CD (0.41) | KDM5ABMPR1AACVRL1ACVR1 | |
| Hydrochloric Acid SCHEMBL31507950 | 0.83 | PIK3CD (0.41) | KDM5ABMPR1AACVRL1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4745131-A1 | PYRIMIDINAMINE NUAK INHIBITOR AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | Technoderma Medicines Inc. (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-12630530-B2 | FGFR inhibitor compound and use thereof | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| US-20260116887-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2026-04-30 | — | — | US | disclosed |
| US-12606544-B2 | JAK1 selective kinase inhibitor | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2026-04-21 | — | — | US | disclosed |
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| EP-4642767-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | Acrivon Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4637738-A2 | INHIBITORS OF JAK2 | Llydaw Therapeutics, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12448382-B2 | Heterocyclic compounds for mediating tyrosine kinase 2 activity | GUANGZHOU INNOCARE PHARMA TECH CO. LTD. (CN) | 2025-10-21 | — | — | US | disclosed |
| US-12421213-B2 | Benzamides of pyrazolylamino- pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2025-09-23 | — | — | US | disclosed |
| WO-2012016082-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-02-02 | — | — | WO | disclosed |
| EP-2401281-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-01-04 | — | — | EP | disclosed |
| CN-102124000-A | Pyridine compounds | ASTRAZENECA AB | 2011-07-13 | — | — | CN | disclosed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| EP-2303861-A1 | PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-20110045999-A1 | IDENTIFICATION OF NOVEL SUBGROUPS OF HIGH-RISK PEDIATRIC PRECURSOR B ACUTE LYMPHOBLASTIC LEUKEMIA, OUTCOME CORRELATIONS AND DIAGNOSTIC AND THERAPEUTIC METHODS RELATED TO SAME | STC.UNM (US) | 2011-02-24 | — | — | US | disclosed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144468-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| WO-2009153589-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | AURKA, AURKC, AURKB | ALOX15 3879/4885GAA 2729/4885SMN1; SMN2 4070/4885 |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | ALOX15 4670/4885GAA 4133/4885SMN1; SMN2 2548/4885 |
| US-12630530-B2 | FGFR inhibitor compound and use thereof | FGFR3, FGFR1, FGFR4 | ALOX15 2773/4885GAA 2785/4885SMN1; SMN2 3320/4885 |
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK1, JAK3, JAK2 | ALOX15 4148/4885GAA 4301/4885SMN1; SMN2 2425/4885 |
| US-20260116887-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | TYK2, JAK2, JAK1 | ALOX15 4120/4885GAA 4786/4885SMN1; SMN2 4544/4885 |
| US-12421213-B2 | Benzamides of pyrazolylamino- pyrimidinyl derivatives, and compositions and methods thereof | JAK2, JAK1, JAK3 | ALOX15 2421/4885GAA 967/4885SMN1; SMN2 3124/4885 |
| US-12606544-B2 | JAK1 selective kinase inhibitor | JAK1, JAK2, JAK3 | ALOX15 994/4885GAA 4701/4885SMN1; SMN2 2782/4885 |
| US-12448382-B2 | Heterocyclic compounds for mediating tyrosine kinase 2 activity | TYK2, JAK2, JAK1 | ALOX15 1094/4885GAA 2522/4885SMN1; SMN2 3995/4885 |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | PTK2, PTK2B, PFKP | ALOX15 1957/4885GAA 3290/4885SMN1; SMN2 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.